Core Viewpoint - Baiyang Pharmaceutical plans to transfer 40.0465% equity of Wuweikang to Baiyang Family Health for 57.4616 million yuan, aiming to optimize asset structure and improve operational efficiency while maintaining collaboration in the home ECG device sector [1] Group 1: Company Actions - Baiyang Pharmaceutical will sign an equity transfer agreement with Baiyang Family Health [1] - The transaction involves transferring 40.0465% of Wuweikang's equity for a total price of 57.4616 million yuan [1] Group 2: Company Profile - Wuweikang is an innovative medical device company currently in the early promotion stage of its products and is operating at a loss [1] - The transaction aligns with Baiyang Pharmaceutical's strategic planning [1] Group 3: Strategic Implications - The transfer is expected to optimize the asset structure of Baiyang Pharmaceutical and enhance asset operational efficiency [1] - Baiyang Pharmaceutical will continue its collaboration with Wuweikang in the home ECG device field [1]